15 March 2018 - The May 2018 PTAC meeting will review the following applications for several new medicines.

The PTAC will consider funding applications for the following medicines: 

• Levofloxacin (Helicobacter pylori infection)
  
• Budesonide (eosinophilic oesophagitis)
  
• Pembrolizumab (urothelial carcinoma)
  
• Atezolizumab (urothelial carcinoma)
  
• Pembrolizumab (Hodgkin’s lymphoma)
  
• Liraglutide (type 2 diabetes melitus)
  
• Adalimumab (ulcerative colitis)
  
• Ustekinumab (Crohn’s disease)
  
• Pirfenidone (idiopathic pulmonary fibrosis)
  
• Mepolizumab (asthma)
  

Read PHARMAC website